Arcus Biosciences (RCUS) Cash from Operations (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Cash from Operations of 138000000.0 for Q1 2026, down 4.55% year-over-year from 144571428.57 in Q1 2025, and down 15.0% quarter-over-quarter from 120000000.0 in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) Cash from Operations (2017 - 2026) Analysis & Trends
Arcus Biosciences' Cash from Operations history runs 10 years deep, the most recent figure standing at 138000000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 4.55% year-over-year to 138000000.0; the TTM figure through Mar 2026 stood at 488000000.0 (down 62.67% YoY), while the FY2025 annual figure was 482000000.0, down 183.53% from the prior year.
- Cash from Operations for Q1 2026 stood at 138000000.0, down from 120000000.0 in the prior quarter.
- The five-year high for Cash from Operations was 654000000.0 in Q1 2022, with the low at 138000000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 88000000.0 (2023), against an average of 38705882.35.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations surged 1086.19% in 2022, then slumped 6500.0% in 2025.
- Arcus Biosciences' Cash from Operations stood at 70000000.0 in 2022, then retreated by 25.71% to 88000000.0 in 2023, then decreased by 13.64% to 100000000.0 in 2024, then slipped by 20.0% to 120000000.0 in 2025, then fell by 15.0% to 138000000.0 in 2026.
- Business Quant data shows RCUS's Cash from Operations at 138000000.0 in Q1 2026, 120000000.0 in Q4 2025, and 97000000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -119.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -119.00 Mn |
| Mar 31, 2026 | -138.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Sep 30, 2025 | -97.00 Mn |
| Jun 30, 2025 | -133.00 Mn |
| Mar 31, 2025 | -132.00 Mn |
| Dec 31, 2024 | -100.00 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | -94.00 Mn |
| Mar 31, 2024 | -2.00 Mn |
| Dec 31, 2023 | -88.00 Mn |
| Sep 30, 2023 | -63.00 Mn |
| Jun 30, 2023 | -57.00 Mn |
| Mar 31, 2023 | -98.00 Mn |
| Dec 31, 2022 | -70.00 Mn |
| Sep 30, 2022 | -81.00 Mn |
| Jun 30, 2022 | -65.00 Mn |
| Mar 31, 2022 | 654.00 Mn |
| Dec 31, 2021 | -61.93 Mn |
| Sep 30, 2021 | -53.76 Mn |